Novo Nordisk's diet drug Novartis has ushered in new developments in the domestic market.

Today, Novo Nordisk announced that Novo Nordisk, the world's first and currently only glucagon-like peptide-1 receptor agonist (GLP-1) weekly formulation for long-term weight management, is officially launched in China.

According to reports, Novartis, also known as the “weight loss version” of simeglutide, can achieve an average weight loss of about 17%, and its weight loss effect can last at least 2 years.

Novo Nordisk revealed that at present, Novo Nordisk is listed in more than 10 countries and regions around the world.

Up to now, simeglutide has accumulated usage experience in more than 22 million patients over the years of exposure.

Some private medical institutions in Shanghai said that Novo Ying has already arrived, and there are many consulting customers. At the same time, I found Yunuo and Yingzai sales on various platforms such as Meituan, Taobao, and Jingdong.

In June of this year, Novo Nordisk announced that the State Drug Administration approved the marketing application for Novo Ying (simeglutide injection for long-term weight management) developed and produced by Novo Nordisk in China.

This drug is the first injection approved for weight loss in China. It is expected to be marketed one after another in mid-November, and the first batch of drugs will enter designated hospitals, pharmacies, weight loss centers, etc.

Previously, Novo Nordisk's hypoglycemic indications for simeglutide injections were approved domestically in 2021.

Then, in July, competitor Eli Lilly's new long-term weight management indications for tirpotide injection (trade name: Mu Fengda) were approved by the State Drug Administration.

The domestic market has huge prospects

With rapid social and economic development, people's living standards have risen, the number of people who are obese has increased, and domestic demand for diet pills has surged.

According to Frost & Sullivan statistics, the number of obese people in China increased from 0.19 billion in 2017 to 0.23 billion in 2021, and is expected to reach 0.33 billion by 2030.

Obesity may increase the risk of diseases such as coronary heart disease, diabetes, and high blood pressure. As the number of obese people increases and residents' awareness of weight management increases, the GLP-1 weight loss market is expected to expand rapidly.

As a result, the diet pills market has broad prospects.

Globally, Goldman Sachs's analytical team has raised the size of the global diet pills market in 2030 from $100 billion at the end of last year to $130 billion.

Domestically, Fangzheng Securities predicts that by 2030, the domestic GLP-1 diet drug market is expected to exceed 37.852 billion yuan.

Furthermore, weight loss drugs have strong consumer properties, mainly rely on personal payments, and are less affected by medical insurance.

In terms of investment, Anxin International believes that since two imported diet pills have been approved for domestic marketing this year, China's weight loss market is expected to usher in a stage of rapid growth. It is recommended to focus on individual stocks related to the GLP-1 weight loss industry chain, such as API manufacturers such as Nuotai Biotech; innovative pharmaceutical companies with advanced R&D progress, such as individual stocks such as Cinda Biotech and Hengrui Pharmaceuticals.

Fangzheng Securities suggests that API layout companies: focus on Nootai Biotech, Hanyu Pharmaceuticals, Shengnuo Biotech, Orient, etc.; CDMO: focus on Gloria Ying, Jiuzhou Pharmaceuticals; innovative pharmaceutical companies: focus on Hengrui Pharmaceuticals, Borui Pharmaceuticals, Cinda Biotech, Lepu Healthcare, Zongsheng Pharmaceutical, etc.